Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference
- Wednesday, March 23, 2022, 7:07
- Finance
- Add a comment
BOSTON and ATLANTA, March 23, 2022 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that Dr. Milton Werner, Ph.D.,…
About the Author
adminasapcorp has written 41789 stories on this site.